Concerning cannabis-related products, and, in connection therewith, changing the basis for marijuana excise and sales tax, moving the testing and safety elements of intoxicating cannabis regulation from the department of revenue to the depar...
SB26-161, titled the "Cannabis Consumer Protection Act," would substantially revise Colorado’s tax and regulatory framework for cannabis-related products. On the tax side, it replaces the current 15% excise tax on the first transfer of unprocessed retail marijuana with a flat $1-per-pound excise tax, adjusted annually for inflation, and replaces the existing 15% retail sales tax with a new tax based on the amount of intoxicating cannabinoids in the product. The bill sets maximum cannabinoid-based sales tax rates that vary by product type and phase in over time, with a higher ceiling after January 1, 2030. It also directs legislative staff and the Joint Budget Committee to review revenue impacts and, if needed, propose future rate adjustments to stabilize tax collections.
The bill also shifts major testing, safety, and product-oversight responsibilities away from the Department of Revenue and the marijuana enforcement division to the Department of Public Health and Environment. It creates a new registration system for intoxicating cannabis product producers, requires statewide off-shelf surveillance testing, and establishes a state reference laboratory to support testing, validation, and public testing services. The bill requires public online access to adverse health reports, traceability data, and testing results for products sold to consumers, and it adds labeling and content-claim requirements for intoxicating cannabis products. It further authorizes the department to order quarantines, relabeling, destruction, recalls, civil penalties, and referrals for license discipline when products are mislabeled or contaminated.
The bill’s impact on state law would be broad. It amends Colorado’s marijuana tax statutes, definitions, licensing provisions, confidentiality rules, and enforcement authorities, while also creating a new section governing intoxicating cannabis products under the public health framework. It would change how cannabis taxes are calculated, how products are tested, where oversight authority resides, and what information must be made available to consumers and regulators. It also affects hemp-derived intoxicating products by bringing certain products under the same registration, testing, and enforcement structure.
Overall sentiment in the available context appears mixed to cautious. The bill’s findings emphasize consumer protection, public health, transparency, and better alignment of oversight with scientific expertise, suggesting strong support from sponsors for a more health-focused regulatory model. At the same time, the bill was postponed indefinitely in the Senate Finance Committee, indicating that the proposal did not advance and likely faced concerns about implementation, revenue effects, regulatory complexity, or the shift in agency authority.
The main points of contention appear to be the tax redesign and the transfer of regulatory power. The new cannabinoid-content tax could raise questions about revenue stability, market effects, and administrative feasibility, which is why the bill includes revenue-projection and adjustment mechanisms. The move of testing and safety oversight from the Department of Revenue to the Department of Public Health and Environment may also have raised concerns among stakeholders about agency capacity, enforcement coordination, and the burden on producers, laboratories, and retailers. Additional tension may stem from expanded public disclosure, mandatory product registration, and stronger recall and penalty authority.
The bill would amend Colorado’s marijuana excise and sales tax statutes by replacing the current percentage-based taxes with a flat excise tax on unprocessed marijuana and a cannabinoid-content-based sales tax on retail cannabis products. It would also create new definitions and tax-adjustment mechanisms tied to inflation and revenue stabilization. On the regulatory side, it would transfer testing and safety oversight for intoxicating cannabis products from the Department of Revenue to the Department of Public Health and Environment, require producer registration, establish a state reference laboratory and off-shelf surveillance testing system, and expand public access to traceability, testing, and adverse health information. These changes would affect marijuana businesses, hemp-derived intoxicating product manufacturers, testing laboratories, and state enforcement agencies.
The bill’s stated purpose reflects a pro-consumer, public-health-oriented approach, with sponsors framing it as a modernization of cannabis regulation to improve safety, labeling, and transparency. However, the lack of recorded committee testimony and the fact that the bill was postponed indefinitely in Senate Finance suggest the proposal did not have enough support to move forward. The overall sentiment in the legislative process appears to have been cautious or unfavorable at the committee stage, likely due to concerns about tax impacts, implementation, and the scope of regulatory restructuring.
The most notable areas of contention are likely the tax changes and the agency transfer. Moving from ad valorem taxes to a per-milligram cannabinoid tax could affect state revenue, consumer prices, and product incentives, and the bill itself anticipates possible revenue instability by directing staff to recommend rate adjustments. Another likely point of dispute is shifting testing, safety, and product-manufacturing oversight to the Department of Public Health and Environment, which would require new infrastructure, staffing, and coordination with the Department of Revenue and the marijuana licensing system. Stakeholders in the cannabis industry may also have concerns about mandatory producer registration, expanded public disclosure of product data, stricter labeling rules, and the bill’s enforcement tools, including recalls, quarantines, and civil penalties.